ANIK (Anika Therapeutics) Institutional Ownership: 93.09% (As of Aug. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ANIK Anika Therapeutics Inc ANIK
58 GF Score
Price $21.50
GF Value $19.18
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Anika Therapeutics Institutional Ownership?

Anika Therapeutics ANIK +1.51% 58 Institutional Ownership is 93.09% as of Aug. 16, 2026. GuruFocus rates ANIK with a GF Score™ of 58/100 and a GF Value™ of $19.18 (Modestly Overvalued). The stock has 4 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Anika Therapeutics's institutional ownership is 93.09%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Anika Therapeutics's Insider Ownership is 11.03%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Anika Therapeutics's Float Percentage Of Total Shares Outstanding is 76.20%.

Anika Therapeutics Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Anika Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anika Therapeutics Institutional Ownership Chart

Anika Therapeutics Historical Data

The historical data trend for Anika Therapeutics can be seen below:

2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30 2026-07-31
Institutional Ownership 29.68 29.60 30.60 30.93 30.89 31.12 31.33 31.64 32.39 31.91
ANIK
58GF Score
Anika Therapeutics Inc ANIK
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anika Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 93.09% mean?
Anika Therapeutics (ANIK) has a Institutional Ownership of 93.09% as of Aug. 16, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Anika Therapeutics and its competitors.
Is Anika Therapeutics' Institutional Ownership too high?
Anika Therapeutics' current Institutional Ownership is 93.09%. Overall, Anika Therapeutics has a GF Score™ of 58/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Anika Therapeutics' Institutional Ownership compare to SIGA and DERM?
Anika Therapeutics' Institutional Ownership of 93.09% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Drug Manufacturers company?
A good Institutional Ownership depends on the Drug Manufacturers industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Anika Therapeutics and its competitors. Anika Therapeutics's current Institutional Ownership is 93.09%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anika Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Anika Therapeutics (ANIK) is currently considered Modestly Overvalued. The stock's GF Value™ is $19.18, compared to a current price of $21.50 — trading 12.1% above its estimated fair value. The current Institutional Ownership is 93.09%. Anika Therapeutics' overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Anika Therapeutics (ANIK), the current Institutional Ownership is 93.09% as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Anika Therapeutics (ANIK) Overvalued in 2026?

Based on GuruFocus' analysis, Anika Therapeutics stock appears to be overvalued. The current stock price of $21.50 is trading 12.1% above its estimated GF Value™ of $19.18. GuruFocus considers Anika Therapeutics to be Modestly Overvalued.

Key valuation signals for ANIK:

  • Institutional Ownership: 93.09%
  • GF Value™: $19.18 vs. price of $21.50 (12.1% above fair value)
  • GF Score™: 58/100 with 4 warning signs

No single metric tells the full story. See the ANIK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Anika Therapeutics Business Description

Other Exchanges AKP:Germany
Address 32 Wiggins Avenue, Bedford, MA, USA, 01730
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.
58GF Score

Get the complete analysis for ANIK

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$21.50
Price
$19.18
GF Value